SPARC2024-04-012024-06-30 SPARC2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member SPARC2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member SPARC2024-04-012024-06-30in-bse-fin:OneOperatingExpenses03Member SPARC2024-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532872 SPARC NA Sun Pharma Advanced Research Company Limited Equity 2024-04-01 2025-03-31 2024-08-05 2024-07-29 INR Lakhs First quarter 11:30:00 14:00:00 2024-08-05 2024-08-05 Not applicable Single segment Pharmaceutical Research and Development 2024-04-01 2024-06-30 Unaudited Standalone 168100000.00 15600000.00 183700000.00 45300000.00 0.00 0.00 289400000.00 5200000.00 27600000.00 784600000.00 1152100000.00 -968400000.00 0.00 -968400000.00 0.00 0.00 0.00 0.00 -968400000.00 0.00 0.00 0.00 0.00 -968400000.00 500000.00 -967900000.00 0.00 0.00 324500000.00 1 -2.98 -2.98 0.00 0.00 -2.98 -2.98 0.00 0.00 0.00 1. The above unaudited standalone financial results of Sun Pharma Advanced Research Company Limited (the 'Company') have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have been taken on record by the Board of Directors at its meeting held on August 5, 2024 after being reviewed by the Audit Committee. 2. The Company has incurred cash losses in past quarters and in the current quarter. However, the Company has unutilized credit limits from its promoter group entity, to support its operations. Further, the Company has also received a financial support letter from its Promoter Group Entity to ensure its status as Going Concern and the continuance of its operations, as and when required. 3. The Company has only one reportable business segment namely 'Pharmaceutical Research and Development'. 4. The figures for the quarter ended March 31, 2024 represent the derived figures between the audited figures in respect of the full financial year ended March 31, 2024 and the unaudited published year-to-date figures upto December 31, 2023, being the date of the end of third quarter of the financial year, which were subjected to a limited review by the statutory auditor of the Company. 5. Previous period figures have been regrouped / reclassified, wherever considered necessary. Clinical trial expenses / products development expense 185400000.00 Other expenses 108200000.00 Professional charges 491000000.00 -500000.00 0.00